How Hypertension During Pregnancy Affects the Fetus

Hypertension during pregnancy poses significant risks to both maternal and fetal health. When high blood pressure develops before 20 weeks’ gestation, it is classified as chronic hypertension; if it arises after 20 weeks—particularly in the absence of proteinuria or other systemic signs—it is termed gestational hypertension. The most concerning complication is preeclampsia: a multisystem disorder characterized by new-onset hypertension (≥140/90 mmHg) after 20 weeks, often accompanied by end-organ damage such as renal impairment (elevated serum creatinine, proteinuria), hepatic dysfunction, thrombocytopenia, cerebral or visual disturbances, or pulmonary edema.

Fetal consequences are substantial and multifactorial. Placental insufficiency—driven by abnormal spiral artery remodeling and endothelial dysfunction—can restrict nutrient and oxygen transfer, leading to intrauterine growth restriction (IUGR) and low birth weight. Reduced placental perfusion also increases the risk of preterm delivery, either iatrogenically (to mitigate maternal deterioration) or spontaneously due to placental abruption. Fetal hypoxia may manifest as abnormal antenatal surveillance findings, including non-reassuring fetal heart rate patterns or decreased biophysical profile scores.

Long-term developmental outcomes are also affected. Infants exposed to hypertensive disorders in utero face elevated risks of neurodevelopmental delays, metabolic syndrome, and early-onset cardiovascular disease later in life—a phenomenon linked to fetal programming and epigenetic modifications. Close antenatal monitoring—including serial ultrasounds for fetal growth and Doppler assessment of umbilical and middle cerebral arteries—is essential. Management hinges on optimizing maternal blood pressure control (typically with labetalol, nifedipine, or methyldopa), timely detection of preeclampsia progression, and individualized timing of delivery based on gestational age and maternal-fetal stability.